ReviewJournal of diabetes and metabolic disorders2026
Possibilities and challenges of next-generation therapeutics: solid lipid nanoparticles revolutionizing metabolic disorder treatment.
Review in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Metabolic disorders (obesity, diabetes mellitus, hyperlipidemia) represent a major and escalating global health burden. Conventional pharmacological therapies face limitations, including poor bioavailability, systemic side effects, and reduced patient compliance. This review explores the potential of solid lipid nanoparticles (SLNs) as an advanced drug delivery system to overcome these limitations and improve the management of metabolic disorders. Methods: The approach involves utilizing SLNs, leveraging their unique physicochemical properties (nanoscale size, biocompatibility, encapsulation capability for both hydrophilic and lipophilic drugs). This enables improved drug solubility, controlled/sustained release, and targeted delivery to specific tissues. SLNs are investigated for delivering agents like antidiabetics, antihyperlipidemics, and anti-obesity drugs, with a focus on overcoming biological barriers (e.g., gastrointestinal tract, blood-brain barrier). Results: SLNs demonstrate significant promise for metabolic disorder therapeutics. Key outcomes include enhanced pharmacokinetics and pharmacodynamics of encapsulated drugs, improved solubility, controlled and sustained release profiles, targeted delivery reducing systemic toxicity, and improved ability to penetrate critical biological barriers, thereby expanding treatment options and potentially enhancing therapeutic efficacy. Conclusion: SLN represents scientific research in the therapeutic approach to obesity, diabetes, and hyperlipidemia. The recent advances offer a highly promising strategy to address the limitations of conventional therapies for metabolic disorders, enhancing drug delivery and targeting while minimizing adverse effects. Despite challenges in drug loading capacity, long-term stability, scalable production, and regulatory pathways, ongoing advancements in nanotechnology. While the path to clinical widespread adoption requires overcoming manufacturing and regulatory obstacles, the continued evolution of SLN technology is poised to play a central role in building the next generation of targeted, effective, and patient-personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.